Cooper Companies operates in two main areas: CooperVision and CooperSurgical. CooperVision makes a wide range of contact lenses to correct vision, supported by product development, manufacturing, and global distribution. CooperSurgical offers medical devices, fertility, and genomic products for women’s health, covering care from contraception through advanced reproductive treatments, with a vertically integrated model that controls research, development, manufacturing, and distribution. Compared with competitors, the company combines vision care and women’s health in one group and maintains end-to-end control of its product lifecycle, enabling integrated supply and service delivery to healthcare providers and patients worldwide. Its goal is to improve health outcomes for people through accessible contact lenses and comprehensive women’s health products and services, across the globe.
Company Size
201-500
Company Stage
IPO
Headquarters
San Ramon, California
Founded
1958
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Paid Vacation
Performance Bonus
Health Insurance
401(k) Retirement Plan
Life Insurance
Wellness Program
Professional Development Budget
The Cooper Companies has opened The Vision Centre, a global innovation hub in Southampton, England, to accelerate contact lens development for its CooperVision business. The facility integrates research and development, clinical expertise, pilot manufacturing and commercial capabilities under one roof. CooperVision announced six product advancements across myopia control, silicone hydrogel, toric and multifocal contact lenses, with launches planned over coming years. The pipeline includes a complete family of one-day contact lenses for myopia control and a premium one-day silicone hydrogel technology. Following the announcement, COO stock gained 1.4%. Year to date, shares have declined 31.6% against the industry's 2.8% growth. The company has a market capitalisation of $10.51 billion. CooperVision's products currently reach more than 40 million people worldwide.
Cooper Companies' shares fell 14.7% on 10 September 2026 after the medical device company reported third-quarter revenue of $1.07 billion, missing analyst expectations of $1.10 billion by $30 million. The company attributed the shortfall to its CooperVision segment, which generated $717 million in quarterly revenue, flat year-over-year. Cooper Companies said it had "proactively reduced U.S. channel inventory" in CooperVision, which would continue to impact fourth-quarter results. The share price dropped from $63.48 to close at $54.17 following the announcement. Law firm Kirby McInerney has announced an investigation into possible securities law violations by the company and its senior management. No lawsuit has been filed yet.
The Cooper Companies cut its fiscal 2026 profit and revenue forecasts after weaker-than-expected contact lens demand affected its CooperVision business. The company now expects adjusted earnings of $4.51–$4.55 per share, down from $4.58–$4.66, whilst revenue guidance was reduced to $4.23–$4.25 billion from $4.29–$4.32 billion. Third-quarter revenue came in at $1.07 billion, below Wall Street's $1.10 billion estimate. CooperVision revenue fell to $717 million, with management citing US channel inventory reductions that are expected to continue affecting the fourth quarter. The company completed its strategic review and decided to retain CooperSurgical rather than sell the business. Despite the challenges, Cooper increased its share-repurchase authorisation from $2 billion to $3 billion.
The Cooper Companies reported third-quarter fiscal 2026 adjusted earnings per share of $1.15, beating the Zacks Consensus Estimate of $1.11 by 3.6%. However, revenues of $1.066 billion missed estimates of $1.099 billion by 3.0%, impacted by US channel inventory reductions in its CooperVision segment. Shares fell 15.9% in after-hours trading following the announcement. The stock has declined 22.5% year-to-date, contrasting with the S&P 500's 11% gain. CooperVision revenues remained flat year over year at $717 million, pressured by inventory destocking. CooperSurgical grew 2% to $349.2 million. MiSight delivered 20% organic growth, whilst MyDay products recorded double-digit growth across multiple categories.
Cooper Companies reported third-quarter fiscal 2026 revenue of $1.066 billion, up about 1%, with non-GAAP earnings per share rising 4% to $1.15. The company generated record quarterly free cash flow of $273 million, bringing year-to-date free cash flow to $528 million, up 86% year over year. CooperVision revenue remained flat at $717 million due to planned US channel inventory reductions, though underlying consumer demand continued growing at mid-single digits. CooperSurgical posted 3% organic growth, with fertility revenue increasing 5% to $141 million. The board concluded its strategic review and decided to retain CooperSurgical, whilst authorising an additional $1 billion in share repurchases. For the fourth quarter, Cooper expects flat to 2% organic revenue growth and non-GAAP EPS of $1.05 to $1.09.